December 7, 2015 Oasmia Pharmaceutical’s Next Generation Anti-cancer Drug Docecal Approved for Clinical Trials Read more
November 20, 2015 Oasmia Pharmaceutical’s Lead Human Cancer Drug Paclical® Generates Strong Interest at the 19th Annual Russian Cancer Congress Read more
November 5, 2015 Oasmia Pharmaceutical AB Confirms Final Data Indicating Positive Top-line Results for Paclical® From Head-to-Head Comparison Study with Abraxane® Read more
November 5, 2015 Oasmia Pharmaceutical AB Announces an Additional and Partial Exercise of Over-Allotment Read more
October 30, 2015 Oasmia Pharmaceutical receives order of $7.5 million in end-user value for the Russian market Read more
October 29, 2015 Oasmia Pharmaceutical AB Announces Closing of U.S. Initial Public Offering of American Depositary Shares and Warrants and NASDAQ Listing Read more
October 28, 2015 Oasmia Pharmaceutical AB Executes First Commercial Order of Paclical for the Russian market Read more
October 23, 2015 Oasmia Pharmaceutical AB Announces Pricing of Public Offering of American Depositary Shares and NASDAQ Listing Read more
October 20, 2015 Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering Read more
October 5, 2015 Oasmia Pharmaceutical AB Announces Commercial Launch of Paclical in Russia and CIS Countries Read more
September 28, 2015 Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering; Adds Warrants Read more
August 17, 2015 Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering; Announces Investor Roadshow Read more
August 4, 2015 Oasmia Pharmaceutical Announces Positive Top-line Results for Paclical® From Head-to-Head Comparison Study with Abraxane® Read more
August 3, 2015 Oasmia Pharmaceutical Extends Form F-1/A Registration Statement to Include New Key Material Data and Final Full-Year Financials Read more
July 7, 2015 Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing Read more
April 20, 2015 Oasmia’s lead cancer product Paclical® receives market approval in the Russian Federation Read more
February 17, 2015 Oasmia initiates clinical Phase II study with Doxophos Vet for the treatment of canine lymphoma Read more
